AI DRIVEN COGINIVITE HEALTH MONITIRING SYSTEM

Jerina Begum S
B.Tech Information Technology
Jerusalem College of Engineering
Chennai, India
jerry.shakeel18@gmail.com

D.S.Thyagaraaj
B.Tech Information Technology
Jerusalem College of Engineering
Chennai, India
thyagaraaj124@gmail.com

P.Barathikannan
B.Tech Information Technology
Jerusalem College of Engineering
Chennai, India
bharathikannanpit2021@jerusalemengg.ac.in

***Abstract*—Neurodegenerative conditions such as Alzheimer's and Parkinson's are highly diagnostic, especially during their initial phases. Traditional diagnostic approaches are based on clinical presentation and neuroimaging, which might fail to identify minute changes in brain structure. This work suggests a hybrid deep learning architecture combining Gray-Level Co-Occurrence Matrix (GLCM)-based texture analysis with a deep learning model, e.g., LSTM or CNN-LSTM, to improve disease prediction from brain MRI scans. The GLCM technique derives essential texture features, retaining structural aberrations, and the LSTM learns temporal patterns of disease progression. The system, by integrating these methods, seeks to enhance the accuracy of early-stage diagnosis, offering an automated and non-invasive method for doctors. The advantages of the model are heightened sensitivity to structural aberrations, enhanced classification accuracy, and a scalable solution for clinical use in neurodegenerative disease detection.**

Keywords: Neurodegenerative Diseases, Alzheimer's, Parkinson's, MRI, Texture Analysis, Brain Imaging, Early Diagnosis.

I. INTRODUCTION

Neurodegenerative conditions, including Alzheimer's and Parkinson's, are an increasingly widespread global health challenge, impacting millions of people and contributing large burdens to healthcare systems. These diseases selectively target the central nervous system, resulting in gradual decline of cognitive and motor functions. Early diagnosis is important for symptom control and slowing the disease process, but existing diagnostic procedures [1] heavily depend on clinical evaluation and neuroimaging modalities that may not detect subtle changes in the brain during early phases. Therefore, more sophisticated computational techniques are needed to improve diagnostic accuracy and make early predictions from neuroimaging information.

Magnetic Resonance Imaging (MRI) is a fundamental tool used to investigate neurodegenerative disorders, which provide detailed structural and functional modifications of the brain. Manual processing of MRI scans is time consuming and prone to differences among radiologists. Techniques that automatically [2] process MRI images are under consideration, as they efficiently retrieve meaningful information from MRI scans. One of the promising methods is texture analysis, and more specifically, the Gray-Level Co-Occurrence Matrix (GLCM), which encodes spatial relationships among pixel intensities in an image. GLCM-based features have been extensively applied in medical imaging to identify abnormalities in tissue structures and are thus extremely relevant for neurodegenerative disease detection.

Deep learning has transformed medical image analysis by offering strong feature extraction and classification capabilities. Convolutional Neural Networks (CNNs) have shown dramatic accuracy in identifying patterns in medical images, yet they concentrate [3] mainly on spatial

features. In contrast, Long Short-Term Memory (LSTM) networks are intended to model temporal dependencies in sequence data. Because neurodegenerative diseases develop over the long term, the integration of CNNs with LSTM networks can improve predictive performance by combining both spatial and temporal features. A combination of deep learning using GLCM for texture analysis and an LSTM model for sequential learning may enhance diagnostic performance. The uniqueness of this work is the use of GLCM-based texture features with an LSTM or CNN-LSTM model for the classification of neurodegenerative diseases. Although CNNs have been commonly employed for MRI-based diagnosis, the inclusion of texture analysis can provide a finer insight into brain structural changes. Furthermore, the LSTM module allows the model to study patterns of disease progression [4], which makes it especially applicable for early detection. This integration of methodologies is intended to yield a more solid and reliable approach to detecting Alzheimer's and Parkinson's based on MRI scans.

Building an automated system for neurodegenerative disease diagnosis can have profound effects on clinical practice. Early and correct diagnosis permits timely intervention, enhancing patients' quality of life and allowing for enhanced disease [5] control. Additionally, an AI-based system can alleviate the burden on radiologists through initial assessments, permitting radiologists to deal with complicated cases that need additional scrutiny. Integration into existing diagnostic workflows can make it easier to implement across medical facilities. While deep learning-based solutions have their own set of benefits, there are issues with the implementation of an efficient system. One such main issue is the requirement for high-quality annotated datasets, since deep learning models take a vast number of annotated MRI scans for training. Another important aspect is to ensure generalizability of the model to populations [6] having different demographics, as variability in MRI acquisition protocols and patient populations can affect performance. Resolving these difficulties involves close collaboration between medical scientists and AI experts to optimize the model and establish its clinical viability. Finally, this study seeks to create a hybrid deep learning model that can utilize GLCM-based texture analysis and LSTM networks to detect Alzheimer's and Parkinson's disease at an early stage via MRI scans. By combining spatial and temporal features, the proposed system seeks to enhance diagnostic accuracy and provide a valuable tool for [7] healthcare professionals. The integration of deep learning into neuroimaging has the potential to revolutionize disease detection, offering a scalable and efficient approach to identifying neurodegenerative conditions in their early stages.

This work is organized with review of the literature survey as Section II. Methodology described in Section III, highlighting its functionality. Section IV discusses the results and discussions. Lastly, Section V concludes with the main suggestions and findings.

II. LITERATURE SURVEY

Neurodegenerative diseases have a great impact on the brain structures and cause cognitive as well as motor impairments. Researchers have sought to utilize MRI-based biomarkers for the identification of early abnormalities in Alzheimer's and Parkinson's disease. Evidence shows that volumetric analysis of brain areas including the hippocampus and substantia nigra is able to supply key information on the progression of disease. More advanced imaging methods, such as diffusion tensor imaging (DTI) and functional MRI (fMRI), have been used to measure structural and functional alterations. These imaging methods provide useful information for early diagnosis but pose challenges to maintaining consistency among various imaging protocols and patient populations.

Machine learning has been more and more applied to aid neurodegenerative disease diagnosis. Several classification methods, such as support vector machines and decision trees, have been used to distinguish between healthy and ill subjects. Feature selection is important for improving model performance [8], with researchers working on extracting informative biomarkers from MRI scans. Although machine learning methods have reported encouraging results in the detection of Alzheimer's and Parkinson's, data sparsity and class imbalance remain significant issues for large-scale clinical adoption. The demand for strong validation methods and extensive datasets continues to be a serious challenge for enhancing model generalizability.

Neurodegenerative disease diagnostic tools are extensively applied for diagnosing neurodegenerative conditions, usually along with neuroimaging. Routine tests like the Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) aid in assessing cognitive impairment. Yet, these are subjective and will not identify early-stage abnormalities. To overcome this limitation, investigators have developed [9] computerized cognitive testing that yields objective and reproducible measures. Such computerized tests incorporate reaction time assessment, memory functions, and language processing evaluation to improve diagnostic sensitivity. Although promising, their utility is subject to patient compliance and standardized administration procedures.

Positron emission tomography (PET) imaging has been well investigated for diagnosing neurodegenerative illnesses through the evaluation of cerebral metabolic rates. PET imaging with radiotracers like fluorodeoxyglucose (FDG) and amyloid-binding [10] ligands has been shown to be highly specific in detecting Alzheimer's pathology. So too, dopamine transporter imaging with single-photon emission computed tomography (SPECT) assists with differentiating Parkinson's disease from other movement disorders. While useful in their diagnostic role, PET and SPECT imaging is expensive, needs specialized facilities, and is associated with radiation exposure, and therefore are restricted from routine use in early detection and population-based screening.

Genetic research has helped elucidate the hereditary components of neurodegenerative disorders. Certain genetic mutations, like APOE ε4 in Alzheimer's and LRRK2 in Parkinson's, have been implicated in elevated disease risk. Genome-wide association studies (GWAS) have revealed numerous susceptibility loci, shedding light on disease mechanisms. Genetic predisposition is not enough for diagnosis [11], though, as environmental and lifestyle factors also contribute significantly. Improvement of polygenic risk scoring and multi-omics methods is also being investigated to improve predictive accuracy. Ethical issues of genetic testing and data privacy continue to be significant issues in clinical and research contexts.

Speech and language analysis has been identified as a non-invasive technique for the detection of early symptoms of neurodegenerative diseases. Alzheimer's patients tend to have language deficiencies, whereas Parkinson's patients have speech dysfunctions like decreased vocal intensity and dysarthria. Acoustic analysis methods [12], such as voice signal processing and natural language processing (NLP), have been used to identify disease-specific patterns. Automated speech testing holds promise for remote monitoring and early intervention. Linguistic variability, accent differences, and ambient noise, however, can impact the validity of speech-based diagnostic tools.

Eye-tracking technology has been investigated as a biomarker for neurodegenerative disease. Alzheimer's and Parkinson's patients exhibit specific patterns of eye movement, including decreased saccadic speed and defective fixation of gaze. Eye-tracking tests can quantify cognitive impairment and [13] motor deficits with high accuracy. Machine learning has been incorporated in recent research to analyze eye movement data for computer-aided diagnosis. The non-invasive method has the benefit of being cost-effective and deployable. Yet more validation is needed for establishing standardized protocols and reproducibility across various populations.

Microbiome studies of the gut have been shown to reveal possible connections between microbiota and neurodegenerative diseases. Dysbiosis in the composition of gut bacteria has been linked with neuroinflammation and the pathophysiology of Alzheimer's and Parkinson's. Research indicates that microbial metabolites affect brain function through the gut-brain axis and influence neurodegeneration. Fecal [14] microbiota transplantation (FMT) and probiotic therapy have been investigated as possible treatments. Although encouraging results have been obtained, heterogeneity in the composition of the gut microbiome among individuals complicates the development of targeted therapies. Additional studies are required to confirm causal associations and define clinical uses for microbiome-based diagnostics.

Sleep disorders are prevalent among neurodegenerative disease patients and can be used as predictors of early onset of the disease. Alzheimer's patients tend to have disturbed sleep-wake cycles, whereas Parkinson's patients commonly [15] have REM sleep behavior disorder (RBD). Polysomnography and wearable sleep monitors have been employed to investigate sleep patterns and their relationship with disease progression. Sleep data have been used to train machine learning models to predict neurodegeneration risk. Nonetheless, such complications as effects of medication as well as co-morbidities may taint sleep-based diagnostics, creating a need to further develop predictive models.

Blood-based biomarkers have emerged as a minimally invasive diagnostic biomarker for neurodegenerative disorders. Protein biomarkers, including amyloid-beta, tau, and alpha-synuclein, were identified in the blood and correlated with Alzheimer's and Parkinson's pathology. Increased sensitivity in ultrasensitive detection methods, i.e., single-molecule [16] arrays and mass spectrometry, has enhanced the quantification of biomarkers. Blood tests provide a scalable approach compared to cerebrospinal fluid (CSF) analysis, but difficulties persist in attaining high specificity and sensitivity. Continued research involves streamlining biomarker panels and combining them with other diagnostic modalities for improved accuracy.

Wearable sensors have been explored for tracking the symptoms of neurodegenerative disease in real-world populations. Smartwatches and motion sensors monitor gait aberrations, tremor, and bradykinesia among Parkinson's patients. Monitoring [17] over time allows disease progression to be detected early on and treatment effect to be monitored. Wearable technology also provides remote monitoring of patients, alleviating the frequency of clinical follow-ups. Different types of sensors, patient compliance, and surrounding environmental conditions raise variability in the data, causing difficulties in normalizing wearable-based diagnostics. Improved algorithms need further research to assure symptom detection without fail.

Olfactory impairment has been recognized as an early indication of neurodegenerative conditions, especially Parkinson's. Symptoms may include impaired ability to sense and discriminate smells, which in some cases precede motor dysfunction by years. Smell tests have been formulated as screening tools [18], but varying degrees of accuracy for diagnosis exist. Electronic nose (e-nose) technology has been studied, where volatile organic compounds indicative of neurodegeneration are sensed by chemical sensors. Although promising, e-nose technology needs to be validated for use in the clinical setting. Nasal conditions, smoking history, and age may affect results.

Resting-state fMRI functional connectivity analysis has been investigated for neurodegenerative disease detection. Abnormal brain network connectivity patterns were found in Alzheimer's and Parkinson's patients that impacted memory [19], motor function, and executive function. Graph-theory-based methods and machine learning models have been used to label disease-related changes in connectivity. Although fMRI-based diagnostics have high accuracy in the research environment, they are hampered in clinical translation by cost, motion artifacts, and issues of standardization. Work is being pursued to improve connectivity biomarkers for

detection at the early stages and tailored treatment planning.

Pharmacologic therapies for neurodegenerative disorders are symptom-modifying and mostly directed against Alzheimer's using cholinesterase inhibitors and NMDA receptor antagonists [20] and Parkinson's with dopamine replacement therapies. Research into disease-modifying drugs, such as monoclonal antibodies against amyloid and tau, has had variable outcomes. Clinical trials for neuroprotective agents, stem cell therapy, and gene therapy are underway. Crossing the blood-brain barrier and long-term safety are, however, continuing to be problems in drug development. Non-pharmacological measures, such as physical exercise and cognitive training, have been tested as a method to slow down neurodegenerative disease. Studies indicate that regular aerobic exercise improves motor symptoms in Parkinson's, while cognitive training enhances memory and executive function in Alzheimer's patients. Multimodal lifestyle interventions incorporating diet, social engagement, and mindfulness have shown potential neuroprotective effects.

III. METHODOLOGY

Neurodegenerative disorders like Alzheimer's and Parkinson's severely affect cognitive and motor skills, so early detection is important to manage them effectively. The conventional methods of diagnosis are based on clinical examination and neuroimaging, which cannot spot the fine alterations in the brain structure. In this work, it is a suggestion to make a hybrid deep learning model combining texture-based feature extraction with the Gray-Level Co-Occurrence Matrix (GLCM) and a deep learning model such as CNN-LSTM. Using MRI scans, the model seeks to identify structural abnormalities that are linked with these diseases. The approach improves accuracy in early-stage diagnosis, providing a non-invasive, computerized tool that aids medical experts in clinical decision-making.

A. Data Collection

Alzheimer's and Parkinson's disease brain MRI datasets are gathered from publicly available databases like ADNI and PPMI, as well as from clinical partnerships. The data contains MRI scans of diagnosed and healthy patients for well-balanced classification. Ethical aspects such as patient permission and anonymization of data are considered. MRI scans collected are tested for quality to eliminate low-resolution or faulty images. The data is separated into training, validation, and testing sets with the assurance that each class is properly represented. Data augmentation processes, including rotation and flipping, are used to increase model generalization.



Fig. 1: Architecture Diagram

B. Preprocessing

Preprocessing is done to improve image quality and to obtain salient features for classification. The MRI scans are initially transformed to a standard format and have skull stripping to eliminate non-brain areas. Filtering methods like Gaussian filtering are used to reduce noise and make the images clearer. Intensity normalization is done to normalize brightness levels in all scans. The images are resized to a fixed size to ensure uniformity in input data. Contrast enhancement methods are applied at the end to emphasize structural variations, enhancing the efficiency of feature extraction algorithms such as GLCM for texture-based analysis in detecting neurodegenerative diseases.

C. Feature Extraction Using GLCM

Gray-Level Co-Occurrence Matrix (GLCM) is employed to extract texture-based features from MRI images to capture structural abnormalities associated with neurodegenerative diseases. GLCM computes spatial relationships between pixel intensities and produces statistical measures like contrast, correlation, energy, and homogeneity. These features quantify patterns in brain tissue that are not readily apparent. Following the computation of GLCM features from preprocessed

images, dimensionality reduction methods such as Principal Component Analysis (PCA) are used to eliminate redundant information. The features extracted are essential input to the deep learning model, which offers useful information regarding texture differences related to disease development.

D. Deep Learning Model Development

A CNN-LSTM hybrid deep learning model is constructed for neurodegenerative disease classification. The CNN part extracts spatial features from MRI images using various convolutional and pooling layers to improve the model's capacity for structural difference recognition. The LSTM block models temporal dependencies and thus is efficient in detecting gradual changes in brain structure. The hybrid CNN-LSTM architecture uses both spatial and sequential features, enhancing the accuracy of classification. Fully connected layers and a softmax activation function are used in the last layers to classify images into Alzheimer's, Parkinson's, or healthy classes. The hybrid model's prediction performance is enhanced by both spatial and temporal information being used.

E. Model Training and Optimization

The data is divided into training, validation, and test sets with an optimal sample distribution. The model is trained with the Adam optimizer and categorical cross-entropy as the loss function. Batch normalization and dropout layers are included to avoid overfitting. The learning rate is adjusted with an adaptive learning rate scheduler. Data augmentation strategies enhance model robustness. Several experiments are performed to find the best number of CNN layers and LSTM units. Regularization techniques such as L2 weight decay are used to improve generalization. The model is tested on the validation set prior to testing on new data.

F. Evaluation

A confusion matrix is computed to study patterns of misclassification. The suggested hybrid model is compared with traditional machine learning models like Support Vector Machines (SVM) and isolated deep models like CNN and LSTM. Statistical significance tests are used to confirm improvement in classification accuracy. Cross-validation methods are used to test the robustness of the model. Performance metrics prove the efficiency of the hybrid CNN-LSTM model for the detection of neurodegenerative diseases and suggest its applicability for clinical use.

G. Deployment and Clinical Integration

The developed model is employed in a decision-support clinical system with automatic prediction of results given MRI scans. A user-friendly system is established for medical users to upload the MRI images and get the resulting classifications. Radiologists and neurologists have an aid of this system when detecting disease conditions at early stages and lowering labor involved in diagnosing manually. Further work incorporates growing the database, enhancing model training for multimodal analysis, and testing for real-world use in clinical applications. The use of AI-powered diagnostic tools may transform neurodegenerative disease identification into a scalable and cost-effective method for early intervention and enhanced patient outcomes.

IV. RESULT AND DISCUSSION

The developed hybrid deep learning model showed impressive accuracy in the diagnosis of Alzheimer's and Parkinson's disease from MRI scans. The integration of GLCM-based texture feature analysis with the CNN-LSTM architecture yielded better classification performance than baseline machine learning models and isolated deep learning methods. The model was able to successfully extract spatial and temporal patterns, facilitating the detection of structural abnormalities linked to neurodegenerative disorders. Discriminative power was strong with AUC-ROC values, validating the robustness of the model to distinguish between healthy and diseased brain scans. Confusion matrix analysis demonstrated low misclassification rates, where most errors arose in instances of feature overlap between Alzheimer's and Parkinson's disease. The model worked well in the identification of early-stage Alzheimer's, which is a significant parameter for prompt intervention. Statistical tests of significance confirmed that performance gains from the hybrid model were not by chance but through its capacity to identify meaningful patterns from MRI scans. Cross-validation also established that the model was generalizable, minimizing overfitting and maximizing reliability with various datasets.

Comparative evaluation against current machine learning methods, including Support Vector Machines (SVM) and Random Forest, underlined the benefit of combining GLCM features with deep learning. Although SVM-based models exhibited good classification performance, they were limited by handling complex texture changes in MRI images. By contrast, the CNN-LSTM model well preserved both high-resolution details and long-term structural evolution, resulting in a better overall evaluation of brain abnormalities. This shows the capability of hybrid deep learning models in medical imaging tasks, particularly for diseases with progressive degeneration.

The assessment also explored the effect of hyperparameter optimization, such as the number of layers of CNN, units of LSTM, and learning rate modifications. The best setups came out in a balance between computational efficiency and prediction performance. Employment of the dropout layers and batch normalization helped curb overfitting substantially, making the model resilient when presented with unknown data. Data augmentation methods also helped optimize model generalization to overcome the paucity of labeled MRI scans. The results indicate that the combination of handcrafted texture features with deep learning can improve the classification of neurodegenerative disease beyond traditional methods.

The results of the study carry direct implications for clinical use, with the model suggested to serve as a non-invasive, computerized diagnostic system for clinicians. The high sensitivity and specificity of the hybrid model make it a worthwhile tool for initial-stage

detection, allowing for early intervention by medical professionals and better outcomes for patients. Subsequent studies will include the enlargement of the dataset, integration of multi-modal imaging methods like PET and CT scans, and optimization of the model using state-of-the-art architectures like transformers. Its deployment in real-world settings in hospitals and research centers may also further establish its clinical effectiveness, filling the gap between AI research and real-world healthcare applications.

V. Conclusion

The research was able to create a hybrid deep learning model which combines GLCM-based texture analysis and a CNN-LSTM framework for the identification of Alzheimer's and Parkinson's disease through MRI scans. The proposed method is able to capture both temporal and spatial features effectively, enabling enhanced classification accuracy in comparison to traditional machine learning and independent deep learning models. By utilizing texture-based feature extraction and deep learning methods, the model shows better performance in detecting neurodegenerative diseases at an early stage, which is important for early medical intervention and better patient outcomes. The results show that the integration of handcrafted GLCM features with deep learning improves the model's capacity to detect subtle structural changes in the brain. The CNN module effectively extracts spatial patterns, and the LSTM module identifies trends in disease progression, resulting in a richer analysis of MRI scans. Statistical analysis also confirms the importance of these gains, showing the reliability and stability of the hybrid method.

One of the strongest aspects of this research is its generalizability across datasets, as shown through cross-validation experiments. Regularization methods like dropout and batch normalization avoid overfitting, keeping the model useful on unseen data. Data augmentation methods also help with better generalization by making up for the scarce number of labeled MRI scans. The comparison with traditional machine learning models emphasizes the benefits of combining both handcrafted and learned features for neurodegenerative disease classification. The results of the study have significant clinical implications, providing a non-invasive, automated diagnostic tool for the early diagnosis of Alzheimer's and Parkinson's disease. The efficiency and accuracy of the hybrid model make it a useful tool for medical practitioners, minimizing dependence on subjective clinical evaluation. Later research will aim to increase the dataset, include multi-modal imaging methods, and probe deeper architectures, including transformers, to continuously improve the model performance. As refinement continues and is validated with real-world cases, this AI method can potentially revolutionize early diagnosis and treatment planning for neurodegenerative diseases.

References

[1] S. Gupta, S. Bose and V. Majhi, "Association of Neurological Family Health History in Parkinson's Diseases," 2024 International Conference on Brain Computer Interface & Healthcare Technologies (iCon-BCIHT), Thiruvananthapuram, India, 2024, pp. 207-212, doi: 10.1109/iCon-BCIHT63907.2024.10882367.

[2] B. Muthusenthil, P. Jeyakani, V. Dhanakoti and B. A. Bharathi, "Mental Health Assistance and Early Detection of Alzheimer and Parkinson Diseases using Deep Learning," 2024 International Conference on Computer Engineering, Network, and Intelligent Multimedia (CENIM), Surabaya, Indonesia, 2024, pp. 1-5, doi: 10.1109/CENIM64038.2024.10882693.

[3] M. Vimaladevi, R. Thangamani, P. S, V. B and T. A, "Prediction of Alzheimer's Disease by Analyzing Handwriting Dynamics Using Machine Learning Algorithms," 2024 5th International Conference on Electronics and Sustainable Communication Systems (ICESC), Coimbatore, India, 2024, pp. 1298-1304, doi: 10.1109/ICESC60852.2024.10690124.

[4] N. Nithiyameenatchi, S. Rajkumar, E. Konguvel, M. Adithya Narayan and B. Balaji, "Analysis of Parkinson's and Alzheimer's Disease Using Various Machine Learning Based Algorithm," 2024 3rd International Conference on Artificial Intelligence For Internet of Things (AIIoT), Vellore, India, 2024, pp. 1-5, doi: 10.1109/AIIoT58432.2024.10574703.

[5] A. Siddiqua, A. M. Oni and M. J. Miah, "A Transfer Learning Approach for Neurodegenerative Disease Classification from Brain MRI Images: Distinguishing Alzheimer's, Parkinson's, and Control Cases," 2024 6th International Conference on Electrical Engineering and Information & Communication Technology (ICEEICT), Dhaka, Bangladesh, 2024, pp. 347-351, doi: 10.1109/ICEEICT62016.2024.10534463.

[6] M. Dixit, A. K. Mishra, I. Kansal, V. Khullar and A. Kumar, "Comparative Analysis of Deep Learning and Machine Learning Models for Alzheimer's and Parkinson's Disease Classification from Medical Images," 2024 International Conference on Electrical Electronics and Computing Technologies (ICEECT), Greater Noida, India, 2024, pp. 1-5, doi: 10.1109/ICEECT61758.2024.10738919.

[7] M. Khan, U. Khan and A. Othmani, "PD-Net: Multi-Stream Hybrid Healthcare System for Parkinson's Disease Detection using Multi Learning Trick Approach," 2023 IEEE 36th International Symposium on Computer-Based Medical Systems (CBMS), L'Aquila, Italy, 2023, pp. 382-385, doi: 10.1109/CBMS58004.2023.00248.

[8] S. G. S. Gadde, S. Kudipudi, B. Vaka and S. K. Vadapalli, "Prediction of new causing proteins for Alzheimer's, Parkinson's, and Huntington's diseases: Protein- Protein Interaction Analysis," 2023 International Conference on Bio Signals, Images, and Instrumentation (ICBSII), Chennai, India, 2023, pp. 1-7, doi: 10.1109/ICBSII58188.2023.10181057.

[9] Y. Bhatt and Y. Hasija, "Comprehensive Review of Machine Learning Approaches for Analysing EEG-Based Neurological Disorders," 2024 15th International Conference on Computing Communication and Networking Technologies (ICCCNT), Kamand, India, 2024, pp. 1-7, doi: 10.1109/ICCCNT61001.2024.10724747.

[10] R. Sinha, N. Kaur, S. Gupta and P. Thakur, "Diagnosis of Parkinson's Disease using Hybrid Ensemble Technique," 2023 International Conference on Ambient Intelligence, Knowledge Informatics and Industrial Electronics (AIKIIE), Ballari, India, 2023, pp. 1-5, doi: 10.1109/AIKIIE60097.2023.10390458.

[11] V. Viswan, N. Shaffi, M. Mahmud, K. Subramanian and F. Hajamohideen, "A Comparative Study of Pretrained Deep Neural Networks for Classifying Alzheimer's and Parkinson's Disease," 2023 IEEE Symposium Series on Computational Intelligence (SSCI), Mexico City, Mexico, 2023, pp. 1334-1339, doi: 10.1109/SSCI52147.2023.10371843.

[12] P. Deepa and R. Khilar, "Parameter-optimized non-invasive speech test for Parkinson's disease Severity Assessment," 2023 Eighth International Conference on Science Technology Engineering and Mathematics (ICONSTEM), Chennai, India, 2023, pp. 1-7, doi: 10.1109/ICONSTEM56934.2023.10142432.

[13] G. R, V. J. Meenakshy Pillai and N. Kunju, "A Class Imbalance Learning Approach to Build an Efficient Machine Learning Model for the Diagnosis of Parkinson's Disease," 2024 1st International Conference on Trends in Engineering Systems and Technologies (ICTEST), Kochi, India, 2024, pp. 01-06, doi: 10.1109/ICTEST60614.2024.10576138.

[14] R. Bediya, R. R N, K. Mishra, K. Kandoi, S. G. Singh and S. Kumar Singh, "A Hybrid Machine Learning Framework to Improve Parkinson's Disease Prediction Accuracy," 2023 6th International Conference on Signal Processing and Information Security (ICSPIS), Dubai, United Arab Emirates, 2023, pp. 33-38, doi: 10.1109/ICSPIS60075.2023.10344260.

[15] S. Chandrasekaran, V. Dutt, N. Vyas and A. Anand, "Fuzzy KNN Implementation for Early Parkinson's Disease Prediction," 2023 7th International Conference on Computing Methodologies and Communication (ICCMC), Erode, India, 2023, pp. 896-901, doi: 10.1109/ICCMC56507.2023.10083522.

[16] D. R, S. M, S. S, G. K. V, P. D. M and M. S, "Feature Extraction and Classification Using Ensemble Method to Enhance Parkinson's Disease Prediction," 2023 Annual International Conference on Emerging Research Areas: International Conference on Intelligent Systems (AICERA/ICIS), Kanjirapally, India, 2023, pp. 1-5, doi: 10.1109/AICERA/ICIS59538.2023.10420274.

[17] A. A. Fakoya and S. Parkinson, "A Novel Image Casting and Fusion for Identifying Individuals at Risk of Alzheimer's Disease Using MRI and PET Imaging," in IEEE Access, vol. 12, pp. 134101-134114, 2024, doi: 10.1109/ACCESS.2024.3412850.

[18] D. Pan et al., "Adaptive 3DCNN-Based Interpretable Ensemble Model for Early Diagnosis of Alzheimer's Disease," in IEEE Transactions on Computational Social Systems, vol. 11, no. 1, pp. 247-266, Feb. 2024, doi: 10.1109/TCSS.2022.3223999.

[19] N. M. Mathkunti, U. Ananthanagu and E. P M, "Brain Disease Parkinson's Diagnosis using VGG-16 and VGG-19 with Spiral and Waves drawings as Input," 2024 IEEE 9th International Conference for Convergence in Technology (I2CT), Pune, India, 2024, pp. 1-5, doi: 10.1109/I2CT61223.2024.10543635.

[20] M. S. Rana et al., "Identification of Genomic Associations Between Parkinson's and Neurodegenerative Diseases Using Bioinformatics Models," 2023 International Conference on Electrical, Computer and Communication Engineering (ECCE), Chittagong, Bangladesh, 2023, pp. 1-6, doi: 10.1109/ECCE57851.2023.10101597.